{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T07:55:58Z","timestamp":1769759758385,"version":"3.49.0"},"reference-count":50,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","diabetesresearchclinicalpractice.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Diabetes Research and Clinical Practice"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1016\/j.diabres.2020.108473","type":"journal-article","created":{"date-parts":[[2020,9,28]],"date-time":"2020-09-28T21:38:41Z","timestamp":1601329121000},"page":"108473","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Comparative clinical study evaluating the effect of adding Vildagliptin versus Glimepiride to ongoing Metformin therapy on diabetic patients with symptomatic coronary artery disease"],"prefix":"10.1016","volume":"170","author":[{"given":"Rehab","family":"Werida","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mahmoud","family":"Kabel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gamal","family":"Omran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmed","family":"Shokry","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tarek","family":"Mostafa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.diabres.2020.108473_b0005","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1056\/NEJMoa0806470","article-title":"10-Year Follow-up of Intensive Glucose Control in Type 2 Diabetes","volume":"359","author":"Holman","year":"2008","journal-title":"N Engl J Med."},{"issue":"2","key":"10.1016\/j.diabres.2020.108473_b0010","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1056\/NEJM199901143400207","article-title":"Atherosclerosis\u2013an inflammatory disease","volume":"340","author":"Ross","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1016\/j.diabres.2020.108473_b0015","doi-asserted-by":"crossref","first-page":"463","DOI":"10.2147\/VHRM.S33194","article-title":"Glimepiride: evidence-based facts, trends, and observations (GIFTS)","volume":"8","author":"Basit","year":"2012","journal-title":"Vasc Health Risk Manag."},{"issue":"9","key":"10.1016\/j.diabres.2020.108473_b0020","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1111\/j.1463-1326.2010.01233.x","article-title":"Vildagliptin add-on to metformin produces similar efficacy and reduced hypoglycaemic risk compared with glimepiride, with no weight gain: results from a 2-year study","volume":"12","author":"Matthews","year":"2010","journal-title":"Diabetes Obes Metab."},{"key":"10.1016\/j.diabres.2020.108473_b0025","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1186\/1475-2840-10-85","article-title":"Early and late effects of the DPP-4 inhibitor vildagliptin in a rat model of post-myocardial infarction heart failure","volume":"10","author":"Yin","year":"2011","journal-title":"Cardiovasc Diabetol."},{"issue":"21","key":"10.1016\/j.diabres.2020.108473_b0030","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1056\/NEJMoa0807646","article-title":"Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein","volume":"359","author":"Ridker","year":"2008","journal-title":"N Engl J Med."},{"issue":"9","key":"10.1016\/j.diabres.2020.108473_b0035","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1055\/s-0030-1255036","article-title":"Effects of one year treatment of vildagliptin added to pioglitazone or glimepiride in poorly controlled type 2 diabetic patients","volume":"42","author":"Derosa","year":"2010","journal-title":"Horm Metab Res."},{"issue":"17","key":"10.1016\/j.diabres.2020.108473_b0040","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1161\/CIRCULATIONAHA.113.003199","article-title":"Targeting interleukin-1 in heart disease","volume":"128","author":"Van Tassell","year":"2013","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.diabres.2020.108473_b0045","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.mvr.2011.03.003","article-title":"Protective role of adiponectin on endothelial dysfunction induced by AGEs: a clinical and experimental approach","volume":"82","author":"Del Turco","year":"2011","journal-title":"Microvasc Res."},{"issue":"21","key":"10.1016\/j.diabres.2020.108473_b0050","doi-asserted-by":"crossref","first-page":"2338","DOI":"10.1161\/CIRCULATIONAHA.111.041418","article-title":"Long-term dipeptidyl-peptidase 4 inhibition reduces atherosclerosis and inflammation via effects on monocyte recruitment and chemotaxis","volume":"124","author":"Shah","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.diabres.2020.108473_b0055","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/S0378-4347(00)82009-5","article-title":"New less temperature-sensitive microchromatographic method for the separation and quantitation of glycosylated hemoglobins using a non-cyanide buffer system","volume":"344","author":"Biss\u00e9","year":"1985","journal-title":"J Chromatogr."},{"issue":"6","key":"10.1016\/j.diabres.2020.108473_b0060","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1093\/clinchem\/18.6.499","article-title":"Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge","volume":"18","author":"Friedewald","year":"1972","journal-title":"Clin. Chem."},{"issue":"1","key":"10.1016\/j.diabres.2020.108473_b0065","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.pharep.2014.07.016","article-title":"Multifactorial effects of vildagliptin added to ongoing metformin therapy in patients with type 2 diabetes mellitus","volume":"67","author":"Str\u00f3zik","year":"2015","journal-title":"Pharmacol Rep."},{"issue":"1","key":"10.1016\/j.diabres.2020.108473_b0070","doi-asserted-by":"crossref","first-page":"118","DOI":"10.14310\/horm.2002.1512","article-title":"Effect of vildagliptin on hsCRP and arterial stiffness in patients with type 2 diabetes mellitus","volume":"14","author":"Zografou","year":"2015","journal-title":"Hormones (Athens). J"},{"issue":"6","key":"10.1016\/j.diabres.2020.108473_b0075","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1038\/ijo.2013.162","article-title":"Effects of the once-daily GLP-1 analog liraglutide on gastric emptying, glycemic parameters, appetite and energy metabolism in obese, non-diabetic adults","volume":"38","author":"Van Can","year":"2014","journal-title":"Int J Obes (Lond)."},{"issue":"6","key":"10.1016\/j.diabres.2020.108473_b0080","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1038\/ijo.2011.158","article-title":"Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide","volume":"36","author":"Astrup","year":"2012","journal-title":"Int J Obes (Lond)."},{"issue":"Suppl 3","key":"10.1016\/j.diabres.2020.108473_b0085","doi-asserted-by":"crossref","first-page":"S368","DOI":"10.2337\/diabetes.51.2007.S368","article-title":"Sulfonylurea stimulation of insulin secretion","volume":"51","author":"Proks","year":"2002","journal-title":"Diabetes"},{"issue":"5","key":"10.1016\/j.diabres.2020.108473_b0090","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1592\/phco.30.5.463","article-title":"Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes mellitus","volume":"30","author":"Neumiller","year":"2010","journal-title":"Pharmacotherapy."},{"issue":"12","key":"10.1016\/j.diabres.2020.108473_b0095","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1111\/dme.12499","article-title":"Comparison of vildagliptin and glimepiride: effects on glycaemic control, fat tolerance and inflammatory markers in people with type 2 diabetes","volume":"31","author":"Derosa","year":"2014","journal-title":"Diabet Med."},{"issue":"9","key":"10.1016\/j.diabres.2020.108473_b0100","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1007\/s00125-012-2592-3","article-title":"Glucagon-like peptide-1 inhibits adipose tissue macrophage infiltration and inflammation in an obese mouse model of diabetes","volume":"55","author":"Lee","year":"2012","journal-title":"Diabetologia"},{"key":"10.1016\/j.diabres.2020.108473_b0105","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/1475-2840-13-32","article-title":"The DPP-4 inhibitor sitagliptin attenuates the progress of atherosclerosis in apolipoprotein-E-knockout mice via AMPK- and MAPK-dependent mechanisms","volume":"13","author":"Zeng","year":"2014","journal-title":"Cardiovasc Diabetol."},{"issue":"5","key":"10.1016\/j.diabres.2020.108473_b0110","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.2337\/diacare.26.5.1535","article-title":"C - reactive protein and Glycemic Control in Adults with Diabetes","volume":"26","author":"King","year":"2003","journal-title":"Diabetes Care"},{"issue":"1","key":"10.1016\/j.diabres.2020.108473_b0115","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.diabres.2005.09.011","article-title":"Improvement in C-reactive protein and advanced glycosylation end-products in poorly controlled diabetics is independent of glucose control","volume":"72","author":"Md Isa","year":"2006","journal-title":"Diabetes Res Clin Pract."},{"issue":"2","key":"10.1016\/j.diabres.2020.108473_b0120","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1177\/1074248413504994","article-title":"Inflammation and atherosclerosis\u2013revisited","volume":"19","author":"Pant","year":"2014","journal-title":"J Cardiovasc Pharmacol Ther."},{"issue":"5","key":"10.1016\/j.diabres.2020.108473_b0125","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1007\/s10557-014-6539-4","article-title":"DPP-4 inhibitors repress NLRP3 inflammasome and interleukin-1beta via GLP-1 receptor in macrophages through protein kinase C pathway","volume":"28","author":"Dai","year":"2014","journal-title":"Cardiovasc Drugs Ther."},{"issue":"1","key":"10.1016\/j.diabres.2020.108473_b0130","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/s12933-017-0551-5","article-title":"The addition of vildagliptin to metformin prevents the elevation of interleukin 1\u00df in patients with type 2 diabetes and coronary artery disease: a prospective, randomized, open-label study","volume":"16","author":"Younis","year":"2017","journal-title":"Cardiovasc Diabetol."},{"issue":"3","key":"10.1016\/j.diabres.2020.108473_b0135","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/j.bbrc.2009.10.015","article-title":"Exendin-4, a GLP-1 receptor agonist, directly induces adiponectin expression through protein kinase A pathway and prevents inflammatory adipokine expression","volume":"390","author":"Hosaka","year":"2009","journal-title":"Biochem Biophys Res Commun."},{"key":"10.1016\/j.diabres.2020.108473_b0140","doi-asserted-by":"crossref","DOI":"10.2337\/dc09-1130","article-title":"Changes in serum adiponectin concentrations correlate with changes in BMI, waist circumference, and estimated visceral fat area in middle-aged general population","volume":"32","author":"Okauchi","year":"2009","journal-title":"Diabetes Care"},{"issue":"1","key":"10.1016\/j.diabres.2020.108473_b0145","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1186\/s12944-016-0372-7","article-title":"Impact of dipeptidyl peptidase-4 inhibitors on serum adiponectin: a meta-analysis","volume":"15","author":"Liu","year":"2016","journal-title":"Lipids Health Dis."},{"key":"10.1016\/j.diabres.2020.108473_b0150","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1186\/1475-2840-12-59","article-title":"Vildagliptin in addition to metformin improves retinal blood flow and erythrocyte deformability in patients with type 2 diabetes mellitus - results from an exploratory study","volume":"12","author":"Berndt-Zipfel","year":"2013","journal-title":"Cardiovasc Diabetol."},{"issue":"10","key":"10.1016\/j.diabres.2020.108473_b0155","doi-asserted-by":"crossref","first-page":"2076","DOI":"10.2337\/dc12-0199","article-title":"Reduction of oxidative stress and inflammation by blunting daily acute glucose fluctuations in patients with type 2 diabetes: role of dipeptidyl peptidase-IV inhibition","volume":"35","author":"Rizzo","year":"2012","journal-title":"Diabetes Care"},{"issue":"1\u20133","key":"10.1016\/j.diabres.2020.108473_b0160","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.vph.2011.05.001","article-title":"Cardiovascular effects of DPP-4 inhibition:beyond GLP 1","volume":"55","author":"Fadini","year":"2011","journal-title":"Vasculpharmacol. Vascul Pharmacol."},{"issue":"11","key":"10.1016\/j.diabres.2020.108473_b0165","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1161\/CIRCRESAHA.114.301958","article-title":"Cardiovascular Actions of Incretin-Based Therapies","volume":"114","author":"Ussher","year":"2014","journal-title":"Circ Res."},{"issue":"3","key":"10.1016\/j.diabres.2020.108473_b0170","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1210\/jc.2004-1711","article-title":"Adiponectinemia in visceral obesity: impact on glucose tolerance and plasma lipoprotein and lipid levels in men","volume":"90","author":"C\u00f4t\u00e9","year":"2005","journal-title":"J Clin Endocrinol Metab."},{"issue":"10","key":"10.1016\/j.diabres.2020.108473_b0175","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.2337\/diacare.46.10.1601","article-title":"Insulin and Sulfonylurea Therapy in NIDDM Patients: Are the Effects on Lipoprotein Metabolism Different Even With Similar Blood Glucose Control?","volume":"46","author":"Romano","year":"1997","journal-title":"Diabetes"},{"issue":"10","key":"10.1016\/j.diabres.2020.108473_b0180","doi-asserted-by":"crossref","first-page":"985","DOI":"10.5551\/jat.RV17025","article-title":"Cardioprotective Effects of High-Density Lipoprotein Beyond its Anti-Atherogenic Action","volume":"25","author":"Nagao","year":"2018","journal-title":"J Atheroscler Thromb."},{"issue":"6","key":"10.1016\/j.diabres.2020.108473_b0185","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1111\/j.1463-1326.2008.01021.x","article-title":"Long-term 2-year safety and efficacy of vildagliptin compared with rosiglitazone in drug-na\u00efve patients with type 2 diabetes mellitus","volume":"11","author":"Rosenstock","year":"2009","journal-title":"Diabetes Obes Metab."},{"key":"10.1016\/j.diabres.2020.108473_b0190","doi-asserted-by":"crossref","unstructured":"Park KS, Kwak S, Cho YM, Park KS, Jang HC, Kim SY, Jung HS. Vildagliptin reduces plasma stromal cell-derived factor-1alpha in patients with type 2 diabetes compared with glimepiride. J Diabetes Investig. 2017; 8(2): 218\u201326.doi:10.1111\/jdi.12572","DOI":"10.1111\/jdi.12572"},{"issue":"5","key":"10.1016\/j.diabres.2020.108473_b0195","doi-asserted-by":"crossref","first-page":"529","DOI":"10.4093\/dmj.2011.35.5.529","article-title":"Comparison of Vildagliptin-Metformin and Glimepiride-Metformin Treatments in Type 2 Diabetic Patients","volume":"35","author":"Jeon","year":"2011","journal-title":"Diabetes Metab J."},{"issue":"4","key":"10.1016\/j.diabres.2020.108473_b0200","first-page":"412","article-title":"Dipeptidyl peptidase IV inhibitors for the treatment of impaired glucose tolerance and type 2 diabetes","volume":"4","author":"Wiedeman","year":"2003","journal-title":"Curr Opin Investig Drugs."},{"issue":"159","key":"10.1016\/j.diabres.2020.108473_b0205","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1111\/j.1742-1241.2007.01692.x","article-title":"Clinical trials programme in monotherapy and combination therapy for type 2 diabetes","volume":"62","author":"Rosenstock","year":"2008","journal-title":"Int J Clin Pract. Suppl."},{"issue":"6","key":"10.1016\/j.diabres.2020.108473_b0210","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1111\/j.1463-1326.2010.01215.x","article-title":"Assessing the cardio-cerebrovascular safety of vildagliptin: meta-analysis of adjudicated events from a large Phase III type 2 diabetes population","volume":"12","author":"Schweizer","year":"2010","journal-title":"Diabetes Obes Metab."},{"issue":"4","key":"10.1016\/j.diabres.2020.108473_b0215","doi-asserted-by":"crossref","DOI":"10.1016\/j.ahj.2011.08.004","volume":"162","author":"White","year":"2011","journal-title":"Am Heart J."},{"issue":"12","key":"10.1016\/j.diabres.2020.108473_b0220","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1001\/jama.2019.13772","article-title":"Effect of Linagliptin vs Glimepiride on Major Adverse Cardiovascular Outcomes in Patients With Type 2 Diabetes: The CAROLINA Randomized Clinical Trial","volume":"322","author":"Rosenstock","year":"2019","journal-title":"JAMA"},{"issue":"2","key":"10.1016\/j.diabres.2020.108473_b0225","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1111\/j.1463-1326.2008.00994.x","article-title":"Fifty-two-week efficacy and safety of vildagliptin vs. glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy","volume":"11","author":"Ferrannini","year":"2009","journal-title":"Diabetes Obes Metab."},{"issue":"3\u20134","key":"10.1016\/j.diabres.2020.108473_b0230","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.brainresbull.2012.08.003","article-title":"Metabolic syndrome, mild cognitive impairment and Alzheimer\u2019s disease\u2014the emerging role of systemic low-grade inflammation and adiposity","volume":"89","author":"Misiak","year":"2012","journal-title":"Brain Res Bull."},{"issue":"3","key":"10.1016\/j.diabres.2020.108473_b0235","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1002\/jcla.20175","article-title":"Relationship of serum adiponectin with blood lipids, HbA(1)c, and hs-CRP in type II diabetic postmenopausal women","volume":"21","author":"Goodarzi","year":"2007","journal-title":"J Clin Lab Anal."},{"issue":"11","key":"10.1016\/j.diabres.2020.108473_b0240","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1111\/j.1463-1326.2012.01626.x","article-title":"Adiponectin increases insulin content and cell proliferation in MIN6 cells via PPAR\u03b3-dependent and PPAR\u03b3-independent mechanisms","volume":"14","author":"Rao","year":"2012","journal-title":"Diabetes Obes Metab."},{"key":"10.1016\/j.diabres.2020.108473_b0245","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/631902","article-title":"Proinflammatory and prothrombotic state in subjects with different glucose tolerance status before cardiovascular disease","volume":"2014","author":"Isordia-Salas","year":"2014","journal-title":"J Diabetes Res."},{"issue":"2","key":"10.1016\/j.diabres.2020.108473_b0250","first-page":"286","article-title":"Evaluation of high sensitivity C-reactive protein and glycated hemoglobin levels in diabetic nephropathy","volume":"23","author":"Roopakala","year":"2012","journal-title":"Saudi J Kidney Dis Transpl."}],"container-title":["Diabetes Research and Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168822720307269?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168822720307269?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T19:13:44Z","timestamp":1759173224000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168822720307269"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12]]},"references-count":50,"alternative-id":["S0168822720307269"],"URL":"https:\/\/doi.org\/10.1016\/j.diabres.2020.108473","relation":{},"ISSN":["0168-8227"],"issn-type":[{"value":"0168-8227","type":"print"}],"subject":[],"published":{"date-parts":[[2020,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparative clinical study evaluating the effect of adding Vildagliptin versus Glimepiride to ongoing Metformin therapy on diabetic patients with symptomatic coronary artery disease","name":"articletitle","label":"Article Title"},{"value":"Diabetes Research and Clinical Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.diabres.2020.108473","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"108473"}}